Changes in the nutritional status of nine vitamins in patients with esophageal cancer during chemotherapy

Abstract

BACKGROUND

Many studies have investigated the relationships between vitamins and esophageal cancer (EC). Most of these studies focused on the roles of vitamins in the prevention and treatment of EC, and few studies have examined the changes in vitamin nutritional status and their influencing factors before and after chemotherapy for EC. Chemotherapy may have a considerable effect on EC patients’ vitamin levels and hematological indicators.

AIM

To research the nutritional status of multiple vitamins in EC patients during chemotherapy and to assess its clinical significance.

METHODS

EC patients admitted to our center from July 2017 to September 2020 were enrolled in this study. Serum concentrations of nine vitamins (A, D, E, B₉, B₁₂, B₁, C, B₂ and B₆), hemoglobin, total protein, albumin, blood calcium, blood phosphorus concentrations and body mass index (BMI) were measured in all EC patients. The changes in nine vitamins, hematological indicators and BMI were compared before and after two cycles of chemotherapy. The possible influential factors were analyzed.

RESULTS

In total, 203 EC patients receiving chemotherapy were enrolled in this study. Varying degrees of vitamin A, D, C and B₂ deficiency and weight loss were found in these patients, and the proportions of vitamin B₂ and vitamin C deficiencies increased significantly after chemotherapy (both P < 0.05). Serum concentrations of vitamins A, C, B₂ and B₆ and BMI before and after chemotherapy were statistically significant (all P < 0.05). Multivariate analysis showed that vitamin A levels significantly differed between male and female EC patients, whereas vitamin D concentration significantly differed in EC patients in different stages (all P < 0.05). Correlations were observed between the changes in serum concentrations of vitamin A and C before and after two cycles chemotherapy and the change in BMI (P < 0.05). Hemoglobin, total protein, serum albumin and blood calcium concentrations significantly decreased in EC patients after chemotherapy (all P < 0.05), while the blood phosphorus level significantly increased after chemotherapy (P < 0.05). Using the difference in vitamin concentrations as the independent variables and the difference in BMI as the dependent variable, logistic regression analysis revealed statistically significant differences for vitamin A, vitamin D and vitamin C (F = 5.082, P = 0.002).

CONCLUSION

Vitamin A, D, C and B₂ were mainly deficient in patients with EC during chemotherapy. Multivitamin supplementation may help to improve the nutritional status, chemotherapy tolerance and efficacy.

Key Words: Esophageal cancer; Chemotherapy; Vitamins; Nutritional status; Body mass index

Core Tip: This retrospective study investigated the changes in serum vitamins before and after chemotherapy for esophageal cancer. Vitamin deficiencies are common in esophageal cancer patients during chemotherapy and may be associated with the change in body mass index. There were correlations between the changes in vitamin A and C concentrations and the change in body mass index during chemotherapy. Vitamin A level after chemotherapy showed a significant difference between males and females, and the vitamin D level after chemotherapy showed a significant difference among different stages. Vitamin supplementation may reduce the adverse effects of chemotherapy and improve the nutritional status.

INTRODUCTION

Esophageal cancer (EC) is the ninth most commonly diagnosed cancer and the sixth leading cause of cancer death worldwide[1]. The incidence and mortality rates of EC are highly heterogeneous in terms of gender, histological type, geographic distribution and race[2]. The morbidity and mortality of EC in China are higher than the global averages[3]. Chemoradiotherapy remains the mainstay of treatment for patients with advanced EC. The most common complications during chemoradiotherapy in EC patients include weight loss, malnutrition, bone marrow suppression, electrolyte disturbances, hypoproteinemia and decreased quality of life[4-7]. Multiple vitamins are involved in the pathogenesis, progression and prognosis of tumors and are closely related to the tumor microenvironment. Vitamin testing is valuable in tumor patients as it can identify whether there is a specific vitamin deficiency and/or justify vitamin therapy. Most clinical studies have shown that vitamin nutritional status varies greatly in tumors of different systems[8]. Although many studies have investigated the relationships between vitamins B, A, D and C with EC, most of these studies focused on the roles of vitamins in the prevention and treatment of EC. Few studies have examined the changes in vitamin nutritional status and their influencing factors before and after chemotherapy for EC.

Many vitamins have antitumor effects and are closely related to the occurrence, progression, prognosis and recovery of tumors. Vitamin supplementation can lower the risk of tumorigenesis and prevent abnormal DNA methylation changes in tumor cells[9]. With the advances in nutritional therapy in China, nutritional screenings, assessments and interventions have increasingly been applied in tumor patients. The standardized nutritional therapies involve three major macronutrients including carbohydrates, proteins and fats and have specific requirements on micronutrients. Nutritional therapy for tumor patients provides nutrients and energy and focuses on the metabolism-regulating roles of nutrients[10]. Vitamin supplementation is a common nutritional therapy for tumor patients in clinical practice. Serum vitamin levels vary among patients with different tumors. Zhang et al[11] analyzed the vitamin nutritional status of approximately 1000 hospitalized tumor patients and found that vitamin B1 concentrations were low in patients with digestive system tumors such as EC and gastric cancer. A study on postoperative nutritional deficiencies in patients with EC or gastric cancer revealed that the incidence of ferritin, folic acid, vitamin B₁₂ and vitamin D deficiencies was 42.86%, 9.52%, 6.35% and 36.67%, respectively, and the vitamin levels were significantly improved after nutritional interventions[12]. In another study[13], most patients with advanced tumors had vitamin (particularly vitamins D, B₆ and C) deficiency symptoms during palliative care, and further analysis revealed a correlation between the degree of vitamin deficiency and clinical discomfort in these patients. Most vitamins were found to be negatively associated with the risk of colorectal and gastric cancer in addition to EC in an observational study, yet interventional treatment failed to demonstrate a clear preventive effect in these malignancies [14].

In the current study, we analyzed the effects of chemotherapeutic drugs on EC patients’ vitamin levels and hematological indicators by detecting the changes in nine vitamins and hematological indicators (e.g., hemoglobin, total protein, serum albumin and electrolytes) before and after chemotherapy, with an attempt to provide evidence for clinical vitamin supplementation and nutritional therapies. Our findings may be valuable for the implementation of tailored nutritional interventions, which will help to reduce chemotherapy-related complications, alleviate treatment resistance and improve chemotherapy efficacy.

MATERIALS AND METHODS

Subjects

In total, 203 EC patients (181 men and 22 women) aged 37-78 yrs (mean: 60.03 ± 7.95 years) who were receiving chemotherapy in our center between July 2017 and September 2020 were enrolled in this study. The vast majority of subjects had esophageal squamous cell carcinoma (n = 192, 94.58%), and 166 patients (81.77%) were in stage III-IV (Table 1). The inclusion criteria were as follows: (1) pathologically confirmed esophageal malignancies, with indications for chemotherapy, regardless of gender; (2) aged 18-80 years; (3) an expected survival of > 6 mo; and (4) a Karnofsky performance status score of ≥ 70 points. The exclusion criteria included: (1) contraindications to chemotherapy; (2) coexisting tumors in other systems; (3) coexisting primary blood diseases or endocrine diseases; (4) coexisting cardiopulmonary dysfunction; and (5) coexisting psychiatric disorders.

Table 1 Baseline data of esophageal cancer patients (n = 203).

Clinical features	n	(%)
Gender
Males	181	89.16
Females	22	10.84
Age
< 60 yr	94	46.31
≥ 60 yr	109	53.69
Tumor stage
II	16	7.88
III	98	48.28
IV	68	33.50
Uncertain	21	10.34
Pathologic type
Squamous cell carcinoma	192	94.58
Nonsquamous cell carcinoma	11	5.42
Treatment
Induction chemotherapy	168	82.76
Postoperative adjuvant chemotherapy	15	7.39
Postrelapse chemotherapy	20	9.85
Primary tumor site
Cervical	14	6.90
Upper thoracic	28	13.79
Middle thoracic	77	37.93
Lower thoracic	84	41.38

Methods

Determination of vitamin concentrations and hematological indicators: Vitamin levels were measured using electrochemiluminescence with an LK3000VI vitamin detector (Tianjin Lanbiao Electronic Technology Development Co., Ltd., Tianjin, China) pre- and postchemotherapy in EC patients. The normal thresholds were as follows: hemoglobin: 137-179 g/L in males and 116-155 g/L in females; total protein: 55-88 g/L; serum albumin: 35-50 g/L; blood calcium: 2.09-2.54 mmol/L; blood phosphorus: 0.89-1.60 mmol/L; vitamin A: 0.52-2.20 mmol/L; vitamin D: 25-200 nmol/L; vitamin E: 10-15 mg/mL; vitamin B₉: 6.8-36.3 nmol/L; vitamin B₁₂: 200-900 pg/mL; vitamin B₁: 50-150 nmol/L; vitamin C: 34-114 mmol/L; vitamin B₂: 4.26-18.42 mg/L; and vitamin B₆: 14.6-72.9 nmol/L.

Chemotherapy regimens: Of these 203 EC patients, 168 were treated with induction chemotherapy, 15 with postoperative adjuvant chemotherapy and 20 with postrelapse chemotherapy. The specific regimens were as follows: (1) squamous cell carcinoma: paclitaxel + platinum; (2) adenocarcinoma: oxaliplatin + fluorouracil; and (3) small cell carcinoma: etoposide + platinum. All of these regimens were repeated every 3 wk.

Statistical methods

SPSS 24.0 statistical software was used for analyzing the data. Normally distributed data were expressed as mean ± SD, and intergroup comparisons were based on the paired-sample t-test. Non-normally distributed data were expressed as quartiles and medians, and the rank sum test was applied for comparisons between two groups. The Spearman method was used to test for correlations between the changes in multiple vitamin serum concentrations (the independent variables) and body mass index (BMI) (the dependent variable) during chemotherapy using. P value < 0.05 was regarded as statistically significant.

RESULTS

Variation in BMI and hematological parameters in EC patients during chemotherapy

BMI declined after chemotherapy in 133 cases (65.52%). The number of patients with anemia increased from 119 before chemotherapy to 182 after chemotherapy. The differences in these proportions were statistically significant (P < 0.05) (Table 2).

Table 2 Changes in body mass index and hematological indicators in esophageal cancer patients before and after chemotherapy [n (%)].

Item	Before chemotherapy	After chemotherapy	χ2/Z	P value
Body mass index (kg/m2)			-2.646	0.008
< 18.5	25 (12.32)	22 (10.84)
18.5-23.9	103 (50.74)	123 (60.59)
> 23.9	75 (36.95)	58 (28.57)
Hemoglobin (g/L)			55.710	< 0.001
Decreased	119 (58.62)	182 (89.66)
Normal	84 (41.38)	21 (10.34)
Serum albumin (g/L)			2.717	0.099
Decreased	34 (16.75)	47 (23.15)
Normal	169 (83.25)	156 (76.85)
Serum calcium (mmol/L)			4.780	0.029
Decreased	21 (10.34)	36 (17.73)
Normal	182 (89.66)	167 (82.27)
Blood phosphorus (mmol/L)			2.382	0.123
Decreased	23 (11.33)	13 (6.40)
Normal	180 (88.67)	190 (93.60)

Vitamin levels in EC patients pre- and postchemotherapy

Vitamin A, C, B₂ and B₆ concentrations significantly differed before and after chemotherapy (all P < 0.05) (Table 3).

Table 3 Vitamin concentrations in esophageal cancer patients before and after chemotherapy.

Item	Before chemotherapy (Q1-Q3) median	After chemotherapy (Q1-Q3) median	Z	P value
Vitamin A (μmol/L)	(0.561-0.980) 0.741	(0.528-0.858) 0.678	-3.465	0.001
Vitamin D (nmol/L)	(33.618-49.939) 41.383	(33.235-46.473) 38.832	-1.599	0.110
Vitamin E (μg/mL)	(10.898-11.673) 11.267	(10.905-11.867) 11.298	-1.678	0.093
Vitamin B9 (nmol/L)	(14.529-23.014) 18.718	(13.859-22.037) 17.539	-1.578	0.115
Vitamin B12 (pg/mL)	(491.023-598.303) 557.219	(491.112-590.338) 546.789	-0.326	0.745
Vitamin B1 (nmol/L)	(75.056-97.909) 84.070	(75.826-93.322) 83.095	-1.477	0.140
Vitamin C (μmol/L)	(34.324-38.543) 36.075	(33.299-37.849) 35.259	-3.824	< 0.001
Vitamin B2 (μg/L)	(4.182-5.050) 4.501	(4.105-4.761) 4.284	-2.631	0.009
Vitamin B6 (nmol/L)	(29.702-33.645) 31.747	(28.875-32.868) 31.363	-2.351	0.019

Q1-Q3: Quartiles 1-3.

Vitamin deficiencies in EC patients undergoing chemotherapy

Deficiencies of vitamin A, D, C and B₂ were detected pre- and postchemotherapy, and the proportion of each of these four vitamin deficiencies increased after chemotherapy. In particular the proportions of vitamin C and B₂ deficiencies (24.46% vs 38.85%) increased significantly (both P < 0.05) (Table 4). Three EC patients had excessively high vitamin A concentrations before chemotherapy, which decreased to normal levels in 2 cases and to vitamin A deficiency in 1 case after chemotherapy. None of the other five vitamin (E, B₉, B₁₂, B₁, B₆) deficiencies were detected during chemotherapy.

Table 4 Vitamin deficiencies in esophageal cancer patients before and after chemotherapy, n (%).

Item	Before chemotherapy		After chemotherapy		χ2	P value
	Normal	Deficiency	Normal	Deficiency
Vitamin A (μmol/L)	163 (81.50)	37 (18.50)	158 (79.00)	42 (21.00)	0.485	0.486
Vitamin D (nmol/L)	194 (95.57)	9 (4.43)	191 (94.09)	12 (5.91)	0.235	0.629
Vitamin C (μmol/L)	155 (76.35)	48 (23.65)	133 (65.52)	70 (34.48)	6.682	0.010
Vitamin B2 (μg/L)	139 (68.47)	64 (31.53)	108 (53.20)	95 (46.80)	9.677	0.002

Changes in hematological indicators in EC patients pre- and postchemotherapy

Hemoglobin, total protein, serum albumin and blood calcium concentrations significantly decreased, and blood phosphorus concentrations significantly increased after chemotherapy (all P < 0.05) (Table 5).

Table 5 Changes in hematological indicators in esophageal cancer patients before and after chemotherapy.

Item	Before chemotherapy (mean ± SD)	After chemotherapy (mean ± SD)	t	P value
Hemoglobin (g/L)	130.070 ± 16.484	115.010 ± 14.584	15.342	< 0.001
Total protein (g/L)	66.572 ± 5.726	64.499 ± 5.528	5.032	< 0.001
Serum albumin (g/L)	38.880 ± 4.138	37.546 ± 3.719	4.355	< 0.001
Blood calcium (mmol/L)	2.240 ± 0.128	2.207 ± 0.132	2.835	0.005
Blood phosphorus (mmol/L)	1.130 ± 0.200	1.180 ± 0.184	-2.818	0.005

SD: Standard deviation.

Factors affecting vitamins and hematological indicators in EC patients

After adjustment for covariates of each indicator before chemotherapy, vitamin A levels after chemotherapy showed a significant difference between males and females. Vitamin D levels after chemotherapy showed a significant difference among different tumor grades (both P < 0.05). No statistically significant differences were shown for the other baseline data (all P > 0.05) (Table 6).

Table 6 Factors affecting various indicators in esophageal cancer patients during chemotherapy.

Item	Gender (Males/females)		Age (≥ 60 yr/< 60 yr)		Tumor grades (grades II/III/IV)		Tumor location (cervical/upper, middle, lower thoracic)
	F	P value	F	P value	F	P value	F	P value
Body mass index	0.014	0.904	0.042	0.837	0.672	0.512	0.718	0.542
Hemoglobin	0.044	0.834	0.757	0.385	0.747	0.475	0.195	0.900
Serum albumin	0.707	0.402	3.387	0.067	0.210	0.811	2.554	0.057
Vitamin A	5.407	0.021	0.059	0.809	0.151	0.860	0.692	0.558
Vitamin D	0.594	0.442	0.326	0.568	6.899	0.001	0.324	0.808
Vitamin C	3.774	0.053	0.537	0.464	2.633	0.075	2.261	0.083
Vitamin B2	0.178	0.674	0.863	0.354	0.381	0.684	2.273	0.081

The descriptive statistics of each indicator before and after chemotherapy are shown in Tables 3 and 5.

Correlation between vitamin concentrations and BMI during chemotherapy in EC patients

There were correlations between the changes in serum vitamin A and C concentrations and the change in BMI before and after chemotherapy (P < 0.05) (Table 7).

Table 7 Relationships between the differences in vitamins before and after chemotherapy and the difference in body mass index before and after chemotherapy in esophageal cancer patients.

Difference in vitamin concentration	Difference in BMI
	r	P value
Vitamin A	0.240	0.001
Vitamin D	-0.080	0.259
Vitamin E	-0.095	0.177
Vitamin B9	-0.016	0.824
Vitamin B12	-0.053	0.449
Vitamin B1	0.021	0.771
Vitamin C	0.188	0.007
Vitamin B2	-0.102	0.149
Vitamin B6	-0.078	0.269

BMI: Body mass index.

Regression analysis of vitamins and BMI in EC patients

Using the difference in vitamin concentrations as the independent variables and the difference in BMI as the dependent variable, logistic regression analysis revealed statistically significant differences for three vitamins (F = 5.082, P = 0.002) (Table 8).

Table 8 Regression analysis of the relationships between the concentrations of various vitamins and body mass index in 203 esophageal cancer patients.

Independent variables (differences)	Dependent variable (difference in BMI)
	B (coefficient)	t	P value
Constant	0.365	4.978	< 0.001
Vitamin A	0.304	1.877	0.062
Vitamin D	-0.009	-2.355	0.020
Vitamin C	0.026	1.793	0.074

BMI: Body mass index.

DISCUSSION

It was found that EC patients had different degrees of vitamin deficiency during chemotherapy, and the hemoglobin, total protein, serum albumin concentration and blood calcium concentration significantly decreased after chemotherapy. In addition, the proportions of patients with weight loss, anemia and hypoproteinemia also significantly increased. Our subjects were most deficient in vitamin B₂ and vitamin C followed by vitamins A and D.

In the current study, EC patients undergoing chemotherapy were most deficient in vitamin B₂ (31.53% and 46.80% before and after chemotherapy, respectively), and vitamin B₂ concentration significantly decreased after chemotherapy (P < 0.05). Vitamin B₁, B₉, B₁₂ and B₆ deficiency or excess was not found in any of our EC patients. A comparison of vitamin levels before and after chemotherapy suggested that vitamin B₆ concentrations decreased significantly after chemotherapy but were still within the normal range. It has been reported that B vitamin intake is correlated with the risk of EC. Appropriate supplementation with vitamins B₆ and B₉ (also known as folate) can reduce the risk, while higher intake of vitamin B₁₂ may increase the risk[15,16]. A study of residents in Yanting County, Sichuan Province, a high-incidence area of EC in China, found that riboflavin intake was markedly deficient, and riboflavin supplements in high-risk groups reduced the incidence of EC[17]. In a multicenter study in China, whole blood riboflavin was tested in 764 EC patients (and in controls), and the analysis revealed that whole blood riboflavin levels were not significantly correlated with the prevalence of EC. However, high whole blood riboflavin level was more favorable for the survival of elderly EC patients aged 50-70 yrs[18]. Therefore, B vitamin supplementation in EC patients undergoing chemotherapy is beneficial to improve vitamin nutritional status and reduce complications.

In our research, the proportion of vitamin C deficiency cases was 23.65% and 34.48%, before and after chemotherapy, respectively. The difference was statistically significant, and vitamin C was the most deficient vitamin after chemotherapy. Thus, chemotherapy may have a considerable effect on vitamin C levels in EC patients. A meta-analysis showed a negative correlation between dietary vitamin C intake and EC risk and concluded that a high level of vitamin C may prevent EC[19]. Vitamin C supplementation was found to downregulate nuclear factor kappa B activity and significantly decrease proinflammatory cytokine levels in EC patients treated with neoadjuvant radiotherapy[20].

In the current study, vitamin A and D deficiencies were found in EC patients both before and after chemotherapy, and their proportions increased following chemotherapy. However, the changes in the proportions were not statistically significant after chemotherapy. Further stratified analysis of the baseline data showed that the change in vitamin A concentration during chemotherapy might be associated with gender, while vitamin D might differ among different tumor stages. Vitamins A and D are mainly derived from food sources. EC itself can affect the intake and absorption of food, and chemotherapy drugs further damage the nutritional status of patients, resulting in more significant vitamin deficiencies in patients after treatment. In the current study, we further analyzed the difference between vitamin concentrations and BMI in EC patients before and after chemotherapy and found that vitamins A and C were significantly correlated with the change in BMI. Regression analysis of multiple vitamins and BMI revealed a statistically significant overall model for three vitamins (A, D and C). Therefore, body weight, vitamin levels and hematological indicators interact with each other during chemotherapy in EC patients, and the supplementation of macronutrients and micronutrients are equally important. Developing holistic care is the key to nutritional therapy for tumor patients.

There were different degrees of vitamin A and D deficiencies in EC patients treated with chemotherapy, and a higher proportion of vitamin A deficiency than vitamin D deficiency and no vitamin E deficiency was detected during our observation. A meta-analysis suggested that vitamin A levels were negatively correlated with EC risk[21], and further studies are needed to confirm whether it affects the prognosis of EC patients. Vitamin D has been found to inhibit tumor cell proliferation, induce cell differentiation, promote apoptosis and suppress angiogenesis[22]. A meta-analysis did not observe an association between vitamin D levels and the development of esophageal lesions[23]. Another study reported that appropriate vitamin D supplementation in postoperative EC patients improved quality of life and disease-free survival, and further multivariate analysis found that vitamin D supplementation was an independent prognostic factor for disease-free survival but was not associated with overall survival[24].

This study had some limitations: (1) the sample size was not large due to the single center retrospective design of the study; (2) a control group was not included, and it is unclear whether vitamin supplementation is beneficial in EC patients undergoing chemotherapy; (3) the results might be biased due to different disease states and chemotherapy regimens; and (4) some patients might have received targeted therapy or immunotherapy during chemotherapy, which may have had an impact on the study results. In addition, no data on response rate or overall survival were included in our analysis, and the relationship between vitamin nutritional status and prognosis in EC patients requires further investigation in multicenter prospective studies.

CONCLUSION

Vitamin deficiencies (mainly vitamins A, D, C and B₂ deficiencies) are common in EC patients during chemotherapy and may be associated with the change in BMI. In addition, chemotherapy drugs decrease hematological indicators such as hemoglobin and albumin. Appropriate nutritional interventions and vitamin supplementation can reduce the adverse effects of chemotherapy, improve overall nutritional status of patients and improve drug tolerability and quality of life.

ARTICLE HIGHLIGHTS

Research background

Few studies have examined the changes in vitamin nutritional status and their influencing factors during chemotherapy for esophageal cancer (EC). Most vitamins were found to be negatively associated with the risk of colorectal and gastric cancer in addition to EC, yet interventional treatment failed to demonstrate a clear preventive effect in these malignancies. In our study, the effects of chemotherapeutic drugs on EC patients’ vitamin levels and hematological indicators were analyzed.

Research motivation

We analyzed the effects of chemotherapeutic drugs on EC patients’ vitamin levels and hematological indicators by detecting the changes in nine vitamins and hematological indicators before and after chemotherapy, with an attempt to provide evidence for vitamin supplementation. Many oncologists believe that vitamin testing is valuable in tumor patients as it can identify whether there is a specific vitamin deficiency and/or justify vitamin therapy. Our findings may be valuable for the implementation of tailored nutritional interventions.

Research objectives

To explore multiple vitamin levels and the possible influential factors in EC patients treated with chemotherapy. Varying degrees of vitamin deficiency and weight loss were found in these patients. Vitamin supplementation may reduce the adverse effects of chemotherapy.

Research methods

Vitamin nutritional status was measured using the electrochemiluminescence method with an LK3000VI vitamin detector before and after two cycles of chemotherapy in EC patients. Statistical analysis was performed using the SPSS 24.0 software package. The latent correlations between multiple vitamin levels (the independent variables) and body mass index (the dependent variable) during chemotherapy were analyzed using the Spearman method.

Research results

Varying degrees of vitamin A, D, C and B₂ deficiency and weight loss were found in EC patients. Statistically significant differences were shown in vitamins A, C, B₂ and B₆ levels and body mass index before and after chemotherapy. Multivariate analysis showed that vitamin A levels significantly differed between male and female EC patients, whereas vitamin D concentrations significantly differed in EC patients in different stages. Correlations were observed between the changes in serum vitamin A and C levels pre- and postchemotherapy and the variation in body mass index.

Research conclusions

Varying degrees of vitamin deficiency and weight loss were found in EC patients undergoing chemotherapy. Vitamin supplementation may help to improve the nutritional status, chemotherapy tolerance and efficacy. To detect the concentrations of vitamins is valuable for EC patients.

Research perspectives

A multicenter prospective study should be performed to reveal the suitable vitamin replenishment programs and potential effects on treatment outcomes and the adverse effects of chemotherapy in EC patients. Thus, randomized control studies and intervention are needed to verify our finding.